Comparison of KADIAN 100 mg When Dosed With Alcohol Under Fasting and Fed Conditions Compared to Water

Inclusion Criteria: * Healthy adult male volunteers, 21 to 40 years of age. * Subjects were non-smokers for at least 3 months or light smokers (less than 10 pack-years). * Subjects with a history of moderate consumption of at least 7-21 units of alcohol per week or the alcohol equivalent (12 oz beer = 5 oz of 80-proof distilled spirits = 1 unit). * Weighing at least 70 kg and within 20% of their ideal weights (table of "Desirable Weights of Adults", Metropolitan Life Insurance Company, 1983). * Medically healthy subjects with no clinically significant abnormalities in their laboratory profile and ECGs, as deemed by the Principal Investigator. * Voluntarily consented to participate in the study. Exclusion Criteria: * History or presence of significant cardiovascular, pulmonary, hepatic, renal, hematologic, gastrointestinal, endocrine, immunologic, dermatologic, neurologic, or psychiatric disease. * In addition, history or presence of: alcoholism or drug abuse; asthma or other chronic respiratory illness; diabetes; gastrointestinal dysmotility, irritable bowel syndrome, chronic constipation or recent enteritis; hypersensitivity or idiosyncratic reaction to morphine or other opioids; hypersensitivity or idiosyncratic reaction to naltrexone, naloxone, or other opioids antagonists. * History of no alcohol intake (alcohol-naive) or less than moderate alcohol intake. * Subject with a history of alcohol intake exceeding the equivalence of 21 units/week or exceeding the average of 3 drinks per day. * Subjects who had a surgery of the gastrointestinal tract (except appendectomy) which would interfere with absorption of the study drug. * Subjects who received hepatic enzyme inducing drugs (e.g. Nizoral, Tagamet) within the previous three months. * Subjects whose QTc interval was \>450 msec at screening and prior to dosing. * Subjects whose sitting blood pressure was less than 110/45 mm Hg at screening or 100/45 mm Hg before dosing. * Subjects who had been on a special diet (for whatever reason) during the 28 days prior to the first dose and throughout the study. * Subjects who had made any significant donation or loss of blood within 56 days. * Subjects who had made a plasma donation within 7 days prior to the study. * Subjects with hemoglobin less than 12.0 g/dL. * Subjects who had participated in another clinical trial within 28 days prior to the first dose. * Subjects who had a positive urine test for drugs of abuse or alcohol. * Subjects who had a positive test for, or had been treated for hepatitis B, hepatitis C or HIV.